While Rigel Pharmaceuticals exceeded analyst expectations for Q4 sales, the significant decrease from the previous year's figures could temper investor enthusiasm. The mixed results present a neutral outlook, as the beat may be seen positively, but the year-over-year decline raises concerns about growth sustainability.